Provided by Tiger Trade Technology Pte. Ltd.

Quoin Pharmaceuticals

6.79
-0.1100-1.59%
Post-market: 6.810.0200+0.29%17:07 EDT
Volume:65.67K
Turnover:443.03K
Market Cap:13.64M
PE:-0.80
High:6.87
Open:6.87
Low:6.66
Close:6.90
52wk High:41.80
52wk Low:3.25
Shares:2.01M
Float Shares:1.30M
Volume Ratio:0.41
T/O Rate:5.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.5210
EPS(LYR):-14.7963
ROE:-575.73%
ROA:-114.60%
PB:3.47
PE(LYR):-0.46

Loading ...

Insider Traders Lose US$65k As Quoin Pharmaceuticals Drops

Simply Wall St.
·
Jul 16

Maxim Group Remains a Buy on Quoin Pharmaceuticals (QNRX)

TIPRANKS
·
Jul 10

Quoin Pharmaceuticals announces FDA clearance of QRX003 IND application

TIPRANKS
·
Jul 09

Quoin Pharma Wins FDA IND Clearance for Qrx003 in Peeling Skin Syndrome

Reuters
·
Jul 09

Quoin Pharmaceuticals Announces Annual Shareholder Meeting

Reuters
·
Jul 07

Quoin Pharmaceuticals receives notice of allowance for QRX003 patent

TIPRANKS
·
Jun 30

Quoin Pharma Wins US Notice of Allowance for Netherton Syndrome Combination-treatment Patent Application

Reuters
·
Jun 30

NASDAQ Trade Halt Volatility Trading Pause at 09:57 Am

Reuters
·
Jun 24

Quoin Pharmaceuticals Ltd : Maxim Group Cuts Target Price to $16 From $40

THOMSON REUTERS
·
Jun 23

Quoin Pharmaceuticals' Potential Skin Disease Treatment Receives US Name Approval

MT Newswires Live
·
Jun 23

Quoin says FDA conditionally approves QYLEKI as brand name for QRX003 Netherton syndrome drug

Reuters
·
Jun 23

Quoin Pharmaceuticals Completes Establishment Of Japanese Subsidiary To Advance Commercial Readiness For Qrx003

Reuters
·
Jun 18

Quoin Pharmaceuticals establishes Japan subsidiary to support QRX003 commercialization plans

Reuters
·
Jun 18

Quoin reports positive pediatric data in Netherton Syndrome program

TIPRANKS
·
Jun 16

Quoin says QRX003 improves 4 of 6 pediatric Netherton syndrome patients in compassionate use program

Reuters
·
Jun 16

Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program

GlobeNewswire
·
Jun 16

Quoin Pharmaceuticals' Skin Disorder Drug Receives Orphan Drug Designation in Japan

MT Newswires Live
·
Jun 04

Quoin says Japan MHLW grants orphan drug status to QRX003 for Netherton syndrome

Reuters
·
Jun 04

Quoin Pharmaceuticals submits QRX003 IND application to FDA

TIPRANKS
·
Jun 02

Quoin Pharmaceuticals submits FDA IND for QRX003 in Peeling Skin Syndrome

Reuters
·
Jun 02